免疫调节剂血管活性肠肽（VIP）对B10.RIII小鼠的实验性自身免疫性葡萄膜炎（EAU）没有影响。
The immunomodulator vasoactive intestinal peptide (VIP) does not affect experimental autoimmune uveitis (EAU) in B10.RIII mice.
作者信息
Chen Jun, Vistica Barbara, Wiggert Barbara, Chan Chi-Chao, Gery Igal
机构信息
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892-1857, USA.
出版信息
Ocul Immunol Inflamm. 2005 Feb;13(1):13-7. doi: 10.1080/09273940490912399.
PURPOSE
Vasoactive intestinal peptide (VIP) exhibits immunomodulatory activities both in vivo and in vitro, including efficient inhibition of murine experimental arthritis. In this study, we investigated the effects of VIP treatment on the induction of experimental autoimmune uveoretinitis (EAU).
METHODS
EAU was induced in B10.RIII mice by immunization with interphotoreceptor retinoid-binding protein (IRBP) using routine methods, but without treatment with pertussis toxin (PTX). VIP was injected i.p. at different doses into mice on alternate days. Mice were tested by conventional methods for ocular inflammation, antibody levels, lymphocyte proliferation, and cytokine release by cultured lymphocytes.
RESULTS
Treatment with VIP, at different doses, had essentially no effect on the development of EAU or antibody production in the B10.RIII mice. The treatment did have variable effects on the low interferon-gamma production by lymphocytes of these mice.
CONCLUSION
Unlike its inhibitory effect in the experimental arthritis system, VIP did not modulate the development of EAU in B10.RIII mice.
目的
血管活性肠肽（VIP）在体内和体外均表现出免疫调节活性，包括有效抑制小鼠实验性关节炎。在本研究中，我们调查了VIP治疗对实验性自身免疫性葡萄膜视网膜炎（EAU）诱导的影响。
方法
采用常规方法，通过用视网膜色素上皮结合蛋白（IRBP）免疫B10.RIII小鼠诱导EAU，但不使用百日咳毒素（PTX）治疗。将不同剂量的VIP隔日腹腔注射到小鼠体内。通过常规方法检测小鼠的眼部炎症、抗体水平、淋巴细胞增殖以及培养淋巴细胞释放的细胞因子。
结果
不同剂量的VIP治疗对B10.RIII小鼠EAU的发展或抗体产生基本没有影响。该治疗对这些小鼠淋巴细胞产生低水平干扰素-γ有不同程度的影响。
结论
与它在实验性关节炎系统中的抑制作用不同，VIP并未调节B10.RIII小鼠EAU的发展。
Zotero 插件